POU SHENG INTERNATIONAL (03813) proposes to appoint Leung Pui Yee as an independent non-executive director.
Bao Sheng International (03813) announced that Mr. Chen Huanzhong will resign from all his positions in the company, including independent non-executive director, chairman of the audit committee, and member of the nomination and remuneration committees, after the shareholders' annual meeting.
Ms. Leung Pui Yee is recommended by the board of directors to be appointed as an independent non-executive director at the shareholders' annual meeting, and if approved, her appointment will take effect after the shareholders' annual meeting. When her appointment becomes effective, Ms. Leung Pui Yee will also serve as chairman of the audit committee and as a member of the nomination and remuneration committees.
POU SHENG INT'L (03813) announced that Mr. Chen Huanzhong will resign from all positions within the company, including independent non-executive director, chairman of the audit committee, and member of the nomination and remuneration committee, after the annual general meeting of shareholders. It was also recommended by the board of directors that Ms. Leung Pui Yee be appointed as an independent non-executive director at the annual general meeting of shareholders, subject to approval, with the appointment taking effect after the conclusion of the meeting. Upon the effective date of such appointment, Ms. Leung Pui Yee will also serve as the chairman of the audit committee and a member of the nomination and remuneration committee.
Related Articles

Power Construction Corporation of China, Ltd (POWERCHINA) has signed a joint venture contract for a 56.36 billion yuan highway design and construction general contracting project.

East China Pharmaceuticals (000963.SZ): The clinical trial application for injectable drug HDM2024 has been approved by the US FDA.

SHOUHUI GROUP (02621) expects a net profit of approximately 780 million to 800 million yuan in 2025.
Power Construction Corporation of China, Ltd (POWERCHINA) has signed a joint venture contract for a 56.36 billion yuan highway design and construction general contracting project.

East China Pharmaceuticals (000963.SZ): The clinical trial application for injectable drug HDM2024 has been approved by the US FDA.

SHOUHUI GROUP (02621) expects a net profit of approximately 780 million to 800 million yuan in 2025.

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


